Testicular Cancer - Pipeline Review, Q2 2011

Global Markets Direct, April 2011, Pages: 105

Testicular Cancer - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Testicular Cancer - Pipeline Review, Q2 2011', provides an overview of the Testicular Cancer therapeutic pipeline. This report provides information on the therapeutic development for Testicular Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Testicular Cancer. 'Testicular Cancer - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Testicular Cancer.
- A review of the Testicular Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Testicular Cancer pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Testicular Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Testicular Cancer pipeline depth and focus of Testicular Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Testicular Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Testicular Cancer
Testicular Cancer Therapeutics under Development by Companies
Testicular Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Testicular Cancer Therapeutics - Products under Development by Companies
Testicular Cancer Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Testicular Cancer Therapeutics Development
NsGene A/S
ZIOPHARM Oncology, Inc.
Menarini Group
Testicular Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Sabarubicin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NsG6 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Paclitaxel + Ifosfamide + Cisplatin + Pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + Ifosfamide + Carboplatin + Stem Cell Transplant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sutent - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bleomycin + Cisplatin + Etoposide + Paclitaxel + Oxaliplatin + Ifosfamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Docetaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Etoposide + Bleomycin + Taxol + G-CSF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Carboplatin + Cyclophosphamide + Etoposide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Carboplatin + Cyclophosphamide + Etoposide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ipilimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Arsenic Trioxide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STI571 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine + GM-CSF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bleomycin Sulfate + Filgrasram + Cisplatin + Etoposide + Ifosfamide + Peripheral Blood Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CBOP + BEP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Total-Body Irradiation + Autologous Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Etoposide + Carboplatin + Autologous Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ras Peptide Vaccine + DetoxPc + Aldesleukin + Sargramostim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Ifosfamide + Vinblastine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sorafenib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Everolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pegfilgrastim + Cisplatin + Ifosfamide + Paclitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dasatinib + Ifosfamide + Carboplatin + Etoposide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Etoposide + Cyclophosphamide + Autologous Bone Marrow Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MEN-10755 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Etoposide + cisplatin + bleomycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bleomycin Sulfate + Pegfilgrastim + Cisplatin + Etoposide + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + carboplatin + cyclophosphamide + epirubicin hydrochloride + etoposide + ifosfamide + paclitaxel + thiotepa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
R-CHOP + liposomal cytarabine + methotrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bleomycin sulfate + Filgrastim + Carboplatin + Cisplatin + Cyclophosphamide + Etoposide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + gemcitabine + paclitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Paclitaxel + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Gemcitabine Hydrochloride + Ifosfamide + Paclitaxel + Filgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vinblastine + Cisplatin + Bleomycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amsacrine + Cisplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Etoposide + Cyclophosphamide + Cisplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zymafos + Etoposide + Carboplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Etoposide + Autologous Bone Marrow Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Etoposide + Autologous Bone Marrow Transplantation/Peripheral Blood Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epirubicin + Paclitaxel + Etoposide + Ifosfamide + Carboplatin + Autologous Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Testicular Cancer Therapeutics - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Testicular Cancer, Q2 2011
Products under Development for Testicular Cancer – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Comparative Analysis by Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
NsGene A/S, 2011
ZIOPHARM Oncology, Inc., 2011
Menarini Group, 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Discontinued Products

List of Figures
Number of Products under Development for Testicular Cancer, Q2 2011
Products under Development for Testicular Cancer – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Customers who bought this item also bought

• Testicular Cancer - Pipeline Review, Q4 2010
• Cervical Cancer - Pipeline Review, H2 2012
• Oral Cancer - Pipeline Review, H2 2012
• Brain Cancer - Pipeline Review, H2 2012
• Bladder Cancer - Pipeline Review, H2 2012
• Lip Cancer - Pipeline Review, H2 2012
• Non-Small Cell Lung Cancer - Pipeline Review, Q4 2010
• Primitive Neuroectodermal Tumor (PNET) - Pipeline Review, H2 2012
• Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2013
• Radiation Toxicity - Pipeline Review, Q3 2011